The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Open accessAbstract
BACKGROUND: Gene expression profiling of breast cancer has identified two biologically distinct estrogen receptor (ER)-positive subtypes of breast cancer: luminal A and luminal B. Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors. In this study, we developed a clinically practical immunohistochemistry assay to distinguish luminal B from luminal A tumors and investigated its ability to separate tumors according to breast cancer recurrence-free and disease-specific survival. METHODS: Tumors from a cohort of 357 patients with invasive breast carcinomas were subtyped by gene expression profile. Hormone receptor status, HER2 status, and the Ki67 index (percentage of Ki67-positive cancer nuclei) were determined immunohistochemically. Receiver operating characteristic curves were used to determine the Ki67 cut point to distinguish luminal B from luminal A tumors. The prognostic value of the immunohistochemical assignment for breast cancer recurrence-free and disease-specific survival was investigated with an independent tissue microarray series of 4046 breast cancers by use of Kaplan-Meier curves and multivariable Cox regression. RESULTS: Gene expression profiling classified 101 (28%) of the 357 tumors as luminal A and 69 (19%) as luminal B. The best Ki67 index cut point to distinguish luminal B from luminal A tumors was 13.25%. In an independent cohort of 4046 patients with breast cancer, 2847 had hormone receptor-positive tumors. When HER2 immunohistochemistry and the Ki67 index were used to subtype these 2847 tumors, we classified 1530 (59%, 95% confidence interval [CI] = 57% to 61%) as luminal A, 846 (33%, 95% CI = 31% to 34%) as luminal B, and 222 (9%, 95% CI = 7% to 10%) as luminal-HER2 positive. Luminal B and luminal-HER2-positive breast cancers were statistically significantly associated with poor breast cancer recurrence-free and disease-specific survival in all adjuvant systemic treatment categories. Of particular relevance are women who received tamoxifen as their sole adjuvant systemic therapy, among whom the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B, and 57% (95% CI = 47% to 69%) for luminal-HER2 subtypes. CONCLUSION: Expression of ER, progesterone receptor, and HER2 proteins and the Ki67 index appear to distinguish luminal A from luminal B breast cancer subtypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 3×
“Positive 35 (10) 507 (13) 0 (0) 0 (0) 222 (100) 222 Negative 277 (78) 3360 (83) 1530 (100) 846 (100) 0 (0) 2376 Uninterpretable 45 (13) 179 ( 4 ) 0 (0) 0 (0) 0 (0) 0”
InfluentialSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 3×
“41 (30-57) 47 (40-55) 64 (59-69) 81 (77-85)”
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Self-citationBreslow, N., Cox, D. R., & Oakes, D. (1985) · Biometrics · doi:10.2307/2530888 · Cited by 4,333
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Self-citationEffect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Self-citationPathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
The molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Self-citationDistinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Self-citationConcordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Self-citationThe Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. E., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,070
Ravdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., & Parker, H. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.980 · Cited by 996
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Bland, J. M., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.328.7447.1073 · Cited by 928
Howell, A. (1998) · PubMed · Cited by 901
Survival probabilities (the Kaplan-Meier method)
Bland, J. M., & Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7172.1572 · Cited by 824
Validation of Tissue Microarray Technology in Breast Carcinoma
Camp, R. L., Charette, L. A., & Rimm, D. L. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780204 · Cited by 799
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
Olivotto, I. A., Bajdik, C. D., Ravdin, P. M., Speers, C. H., Coldman, A. J., Norris, B. D., Davis, G. J., Chia, S. K., & Gelmon, K. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.178 · Cited by 567
Self-citationViale, G., Regan, M. M., Maiorano, E., Mastropasqua, M. G., Dell'Orto, P., Rasmussen, B. B., Raffoul, J., Neven, P., Orosz, Z., Braye, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9453 · Cited by 452
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
Yaziji, H. (2004) · JAMA · doi:10.1001/jama.291.16.1972 · Cited by 438
Stuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008) · The Breast · doi:10.1016/j.breast.2008.02.002 · Cited by 431
Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201966.23445.91 · Cited by 386
Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast Cancers
Oh, D. S., Troester, M. A., Usary, J., Hu, Z., He, X., Fan, C., Wu, J., Carey, L. A., & Perou, C. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2755 · Cited by 356
Self-citationNocito, A., Bubendorf, L., Tinner, E. M., Süess, K., Wagner, U., Forster, T., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., et al. (2001) · The Journal of Pathology · doi:10.1002/1096-9896(200107)194:3<349::aid-path887>3.0.co;2-d · Cited by 317
Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj357 · Cited by 286
Viale, G., On the behalf of the International Breast Cancer Study Group, Regan, M. M., On the behalf of the International Breast Cancer Study Group, Mastropasqua, M. G., On the behalf of the International Breast Cancer Study Group, Maffini, F., On the behalf of the International Breast Cancer Study Group, Maiorano, E., On the behalf of the International Breast Cancer Study Group, et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm289 · Cited by 247
Joensuu, H., Isola, J. J., Lundin, M., Salminen, T. M., Holli, K., Kataja, V. V., Pylkkänen, L. H., Turpeenniemi-Hujanen, T. M., von Smitten, K., & Lundin, J. E. (2003) · PubMed · Cited by 207
Cheang, M. C. U., Treaba, D. O., Speers, C. H., Olivotto, I. A., Bajdik, C. D., Chia, S. K., Goldstein, L. C., Gelmon, K. A., Huntsman, D., Gilks, C. B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4155 · Cited by 206
Self-citationEllis, M. J., Coop, A., Singh, B., Yu, T., Llombart‐Cussac, A., Jänicke, F., Mauriac, L., Quebe‐Fehling, E., Chaudri‐Ross, H. A., Evans, D. B., et al. (2003) · PubMed · Cited by 202
Self-citationTrihia, H., Murray, S., Price, K., Gelber, R. D., Golouh, R., Goldhirsch, A., Coates, A. S., Collins, J., Castiglione‐Gertsch, M., & Gusterson, B. A. (2003) · Cancer · doi:10.1002/cncr.11188 · Cited by 189
Keshgegian, A. A., & Cnaan, A. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.1.42 · Cited by 184
Technology Insight: identification of biomarkers with tissue microarray technology
Giltnane, J. M., & Rimm, D. L. (2004) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0046 · Cited by 161
Voduc, D. K., Cheang, M. C. U., & Nielsen, T. O. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1090 · Cited by 158
Self-citationMarcom, P. K., Isaacs, C. J., Harris, L. N., Wong, Z. W., Kommareddy, A., Novielli, N., Mann, G., Tao, Y., & Ellis, M. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9307-8 · Cited by 154
Self-citationLiu, S., Chia, S., Mehl, E., Leung, S. C. Y., Rajput, A. B., Cheang, M. C. U., & Nielsen, T. O. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0318-0 · Cited by 123
Self-citationLiu, S., Edgerton, S. M., Moore, D. H., & Thor, A. D. (2001) · PubMed · Cited by 122
Gene Expression Profiling of Breast Cancer
Cheang, M. C. U., van de Rijn, M., & Nielsen, T. O. (2007) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151505 · Cited by 109
Self-citationChong, S. F., & Choo, R. W. M. (2011) · Proceedings of Singapore Healthcare · doi:10.1177/201010581102000314 · Cited by 107
Brown, L. A., Irving, J., Parker, R. L., Kim, H., Press, J. Z., Longacre, T. A., Chia, S., Magliocco, A. M., Makretsov, N. A., Gilks, C. B., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.026 · Cited by 92
Self-citationClahsen, P. C., de Velde, C. J. H. V., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroïde, A., van den Broek, L., & van de Vijver, M. J. (1999) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0657 · Cited by 90
Compliance with practice guidelines for node-negative breast cancer.
Olivotto, A., Coldman, A. J., Hislop, T. G., Trevisan, C. H., Kula, J., Goel, V., & Sawka, C. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.216 · Cited by 80
Mullins, M., Perreard, L., Quackenbush, J. F., Gauthier, N. P., Bayer, S., Ellis, M. J., Parker, J. S., Perou, C. M., Szabó, A., & Bernard, P. S. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.083725 · Cited by 73
Self-citationDomagała, W., Markiewski, M. M., Harezga, B., Dukowicz, A., & Osborn, M. (1996) · PubMed · Cited by 68
The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67
Goodson, W. H., Moore, D. H., Ljung, B., Chew, K., Mayall, B. H., Smith, H. S., & Waldman, F. M. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006344010050 · Cited by 47
Controversies in the Assessment of HER-2
Leong, T. Y.-M., & Leong, A. S. ‐. (2006) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000213043.16200.92 · Cited by 29
Bevilacqua, P., Verderio, P., Barbareschi, M., Bonoldi, E., Boracchi, P., Palma, P. D., & Gasparini, G. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806494 · Cited by 19
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationMetastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Self-citationDowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Self-citation
Metadata
- Authors
- Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., Perou, C. M., Ellis, M. J., & Nielsen, T. O.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-20
- Volume
- 101
- Issue
- 10
- Pages
- 736-750
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2127057139
- Cited by
- 2,249
- References
- 61
- FWCI
- 37.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.